A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2016
At a glance
- Drugs TSB 9-W1 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 22 Apr 2016 Planned number of patients changed from 58 to 30.
- 22 Apr 2016 Focus of the trial changed from TU+AR to AR as primary end point "Disease control rate" is removed. Phase of the trial changed from phase I/II to phase I and thus change in title.
- 22 Apr 2016 Planned initiation date changed from 1 Nov 2014 to 1 May 2016.